endo-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxamide | 142942-75-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: endo-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxamide
• 英文别名: endo-2,3-dihydro-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2-oxo-1H-benzimidazole-1-carboxamide；DA 6215; Dau 6215CL;U 98079A；N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-2-oxo-3H-benzimidazole-1-carboxamide
• CAS: 142942-75-4
• 化学式: C₁₆H₂₀N₄O₂
• 分子量: 300.36
• InChiKey: RWXRJSRJIITQAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  64.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  endo-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxamide 生成 3-ethyl-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-2-oxobenzimidazole-1-carboxamide;hydron;chloride
  参考文献：
  名称：

  J. Med. Chem. 1990, 33, 2101-2108

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氨基托烷 、 (9ci)-2,3-二氢-2-氧代-1H-苯并咪唑-1-羰酰氯 在 3-氨基托烷 作用下， 生成 endo-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxamide
  参考文献：
  名称：

  J. Med. Chem. 1990, 33, 2101-2108

  摘要：

  DOI：

文献信息

• Formulations of adenosine a1 agonists
  申请人：——

  公开号：US20030018008A1

  公开（公告）日：2003-01-23

  The present invention provides a method of treating conditions associated with pain and alleviating the symptoms associated therewith which comprises administering to a mammal, including man, an adenosine A1 agonist or a physiologically acceptable salt or solvate thereof and a 5HT 3 antagonist or a physiologically acceptable salt or solvate thereof. The present invention also provides pharmaceutical formulations and patient packs comprising said combinations.

  本发明提供了一种治疗与疼痛相关的症状并缓解相关症状的方法，包括向哺乳动物，包括人类，施用腺苷A1受体激动剂或其生理上可接受的盐或溶剂以及5HT3拮抗剂或其生理上可接受的盐或溶剂。本发明还提供了包含这些组合物的药物配方和患者包。
• Active agent delivery systems and methods for protecting and administering active agents
  申请人：New River Pharmaceuticals Inc.

  公开号：US20040063628A1

  公开（公告）日：2004-04-01

  The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

  本发明涉及活性物质输送系统，更具体地涉及包含氨基酸，作为单个氨基酸或肽的组成部分，与活性物质共价连接的组合物和用于给予共轭活性物质组合物的方法。
• Combination treatment for depression
  申请人：——

  公开号：US20020107244A1

  公开（公告）日：2002-08-08

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a 5-HT3 receptor antagonist in combination with an SRI antidepressant agent with improvement in sexual function and/or reduction in gastro-intestinal side effects. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5-HT3 receptor antagonist and an SRI antidepressant.

  本发明涉及一种治疗哺乳动物，包括人类的抑郁症或焦虑症的方法，通过给哺乳动物同时注射5-HT3受体拮抗剂和SRI抗抑郁剂来改善性功能和/或减少胃肠道副作用。它还涉及含有药用载体、5-HT3受体拮抗剂和SRI抗抑郁剂的制药组合物。
• ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS
  申请人：Mickle Travis

  公开号：US20090253792A1

  公开（公告）日：2009-10-08

  The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

  本发明涉及活性剂递送系统，更具体地涉及包含氨基酸（作为单个氨基酸或肽）与活性剂共价连接的组合物以及给予共轭活性剂组合物的方法。
• ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS
  申请人：Mickle Travis

  公开号：US20090306228A1

  公开（公告）日：2009-12-10

  The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

  本发明涉及活性剂递送系统，更具体地涉及包含氨基酸，作为单个氨基酸或肽，与活性剂共价结合的组合物以及用于给予共轭活性剂组合物的方法。